April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Leucine-rich repeat kinase 2 (LRRK2) deficiency diminishes the development of EAU
Author Affiliations & Notes
  • Sylvia Wandu
    Laboratory of Immunology, National Eye Institute, Bethesda, MD
  • Guangpu Shi
    Laboratory of Immunology, National Eye Institute, Bethesda, MD
  • Osato Ogbeifun
    Laboratory of Immunology, National Eye Institute, Bethesda, MD
  • Lindsey Nugent
    Laboratory of Immunology, National Eye Institute, Bethesda, MD
  • Huaibin Cai
    Laboratory of Neurogenetics, National Institute of Aging, Bethesda, MD
  • Igal Gery
    Laboratory of Immunology, National Eye Institute, Bethesda, MD
  • Footnotes
    Commercial Relationships Sylvia Wandu, None; Guangpu Shi, None; Osato Ogbeifun, None; Lindsey Nugent, None; Huaibin Cai, None; Igal Gery, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sylvia Wandu, Guangpu Shi, Osato Ogbeifun, Lindsey Nugent, Huaibin Cai, Igal Gery; Leucine-rich repeat kinase 2 (LRRK2) deficiency diminishes the development of EAU. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The gene leucine-rich repeat kinase 2 (LRRK2) instructs the formation of a protein, Dardarin, that plays an important role in the neural system; mutations of this gene are responsible for certain forms of Parkinson’s disease. Deficiency of LRRK2 was reported to enhance the development of experimental colitis (Liu et al. Nature Immunol., 2011). Here, we examined the effect of LRRK2 deficiency on the development of experimental autoimmune uveitis (EAU) and related immune responses.

Methods: Conventional methods were used for the induction of EAU in LRRK2 deficient mice (“KO”) and their wild type C57Bl/6 controls (“WT”) and the disease development was assessed by histological analysis on day 14 post-injection (p.i.). Draining lymph nodes were collected on day 14 p.i. and their cells were analyzed for their responsiveness to the immunizing antigen, interphotoreceptor retinal-binding protein (IRBP), by their enhanced proliferation and release of IL-17 and interferon gamma, using conventional assays. The proportion of T-regulatory cells (Treg) expressing FoxP3, was determined by flow cytometry.

Results: Totals of 28 KO mice and 31 WT controls, in five individual experiments, were tested. Mean EAU severity was scored at 0.54+/-0.19 in KO mice and 1.75+/-0.44 in WT mice (p <0.009). Differences between the two groups in their lymphocyte responses to IRBP and release of IFN-gamma and IL-17, however, were inconsistent. Preliminary data indicate that the proportion of FoxP3 positive cells was higher in the KO mice than that in their WT controls.

Conclusions: Unlike the increased severity of colitis noted in LRRK2 deficient mice, EAU development was reduced in KO mice than in the WT controls. Additional studies are needed to further examine this unexpected difference.

Keywords: 746 uveitis-clinical/animal model • 557 inflammation • 432 autoimmune disease  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×